Latest News for Yappn Stock (OTC:YPPN)

Yappn Corp is a development stage company delivering real-time language translation products. The company's products help vendors and consumers to communicate freely with one another in their own preferred languages. It provides a simple word-for-word translation by translating words as well as the context and syntax, ensuring that what is written in one language is translated into another in the accurate and meaningful way. The company's products are used for eCommerce, customer care, enhanced messaging collaboration such as intranets, gaming or social platforms, online marketing, and custom translation solutions for entertainment, retail, and marketing. It derives the majority of the revenue from the translation services it provides.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

ABEO

ADAP

ADTR

ADXS

AETUF

AGHI

ALKS

AMGDF

ARGGY

ASMB

ASNA

Alterity Therapeutics Limited - American Depositary Shares

ATHE

ATRA

AVRI

AXAS

BCEFF

BCEL

BDIC

BEWFF

BGFV

BIEI

BJCHY

BJRI

BKRIF

BKUT

BLIN

BMYMP

BNDSF

BNDSY

BNIKF

BOTH

BRSWQ

CAIXY

CARB

CBGPY

CBIS

CDEV

CEIX

CESDF

CGLDF

CHKDG

CINR

CLUB

CLVS

CMSQY

CNKEF

COIHF

CORV

China Shenhua Energy Unsponsored representing A shares

CSUAY

CTRA

CUAEF

Changyou Limited American Depositary Share

CYOU

CYTX

DBLVF

DCTH

DKGH

DLTH

DMIFF

DNJR

DPDW

DPGYF

DVAX

ETRN

EVAHF

EXPR

FCUUF

FELP

FNJN

FOMX

FPLSF

FRAC

FURGF

FVANF

GARB

GNFT

GPOR

GTHR

Stocks That Managed to Breach 52-Week Lows Friday

Yappn Corp

Valley Ntl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLY#NASDAQ">VLY</a>) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.20 by 5 percent. This is a 36.67 percent decrease over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $454.963 million which missed the analyst consensus estimate of $455.121 million by 0.03 percent. This is a 7.21 percent decrease over sales of $490.319 million the same period last year.

Earnings

Earnings Misses

Valley Ntl Q1 2024 Adj EPS $0.19 Misses $0.20 Estimate, Sales $454.963M Miss $455.121M Estimate

Biotech

Health Care

ALDX

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day

PPBT

Purple Biotech Says Randomized Phase 2 CM24 Pancreatic Cancer Study Selected As Late-Breaking Abstract Poster Presentation At ASCO 2024 Annual Meeting

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and maintains $40 price target.

Price Target

Reiteration

Analyst Ratings

CAPR

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target

Are you tired of relying solely on dividend stocks for passive income? While they can be a great source of cash flow, putting all your eggs in the stock market basket comes with serious risks. Just look at what happened with AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) in 2022.
For decades, AT&amp;T was a beacon of stability for income investors, reliably increasing its dividend year after year. But then, seemingly out of nowhere, the telecom giant slashed its payout by a staggering 47%. It was a painful reminder that even the most trusted dividend darlings can leave investors high and dry.
To be fair, AT&amp;T still offers a tempting 6.7% yield today. But its total return since the cut is a meager 3.3%, weighed down by an 8% drop in share price. The AT&amp;T saga underscores the dangers of over-relying on any one company or sector for income.
But here&#8217;s the good news: There are plenty of alternative income investments out there that can provide more stable, reliable returns without the stomach-churning volatility of the stock market. And we&#8217;ve done the legwork to uncover four of the most compelling options, with yields ranging from 6% all the way up to 14%.
<h2 class="wp-block-heading">Stable Returns for Risk-Averse Investors: The Ascent Income Fund</h2>
For the risk-averse, the Ascent Income Fund is a standout choice. This diversified real estate debt fund is capitalizing on rising interest rates and reduced lending competition to deliver a target annualized net return of 11%-12%, with quarterly distributions. By focusing on first-lien debt investments across a range of borrowers, geographies and property types, the Fund aims to mitigate risk and provide the stability income-seekers crave.
<a href="https://www.benzinga.com/go/equitymultiple-yf">Click here to learn more about the Ascent Income Fund.</a>
<h2 class="wp-block-heading">6%+ Yield for Short-Term Investors: Alpine Notes</h2>
Looking for a shorter-term play? Check out EquityMultiple&#8217;s Alpine Notes, which offer fixed annual returns of 6% to 7.4% for investment terms of just 3, 6 or 9 months. These innovative cash management tools not only provide competitive yields, but also come with First Loss Protection &#8211; meaning EquityMultiple has skin in the game, investing alongside you in a subordinate position. With over $78M invested across more than 50 Alpine Notes series, they&#8217;ve built a solid track record.
<a href="https://www.benzinga.com/go/equitymultiple-alpine-yf">Discover how much you could earn with Alpine Notes.</a>
<h2 class="wp-block-heading">Stable Income Backed by the Growing Home Equity Market: Cityfunds Yield Fund</h2>
For investors who want to tap into the booming home equity market, the Cityfunds Yield fund is an intriguing option. Targeting an 8% annualized yield (with a 7% guaranteed floor), the fund invests in a diversified pool of collateralized real estate loans, including home equity agreement-backed notes and short-term mortgage notes. With quarterly distributions and a low $500 minimum investment, it&#8217;s an accessible way to get exposure to this growing asset class.
<a href="https://www.benzinga.com/go/cityfunds-yield-YF">Explore the Yield fund</a> and other <a href="https://www.benzinga.com/go/cityfunds-yf">Cityfund offerings</a> here.
<h2 class="wp-block-heading">14% Target Yield for Growth-Oriented Investors: Express Car Wash</h2>
And for those willing to take on a bit more risk in pursuit of outsized returns, feast your eyes on the Express Car Wash investment. With a juicy 14% target return and monthly distributions, this senior loan opportunity is funding the construction of a new Flo&#8217;s Express Car Wash in a prime LA location. And it&#8217;s not just a one-off &#8211; EquityMultiple has a proven track record in the space, with eight car wash exits delivering annualized returns of 13.40% to 85.00%.
<a href="https://www.benzinga.com/go/equitymultiple-yf">Get the full scoop on the Express Car Wash investment.</a>
The bottom line? Diversifying beyond dividend stocks is a smart move for any income-focused investor. While AT&amp;T&#8217;s dividend cut dealt a blow to many portfolios, it also served as a wake-up call about the risks of over-concentration. By spreading your bets across uncorrelated alternative assets like these, you can potentially lock in more stable, reliable cash flows &#8211; without losing sleep over every market dip.
Of course, no investment is without risk, and due diligence is always a must. But if you&#8217;re looking to level up your passive income game in the wake of the AT&amp;T disappointment, these four high-yield options are a great place to start.
Check out the opportunities best suited for your investment goals and start building a more resilient income portfolio today.

Dividends

Tired of Unreliable Dividends? Check Out These 4 High-Yield Alternatives

HOOK

HOOKIPA Pharma Announced Its Final Pivotal Phase 2/3 Trial Design For HB-200 In Combination With Pembrolizumab Based On Alignment With The FDA

ONCY

Oncolytics Reports Acceptance Of Two Abstracts At The 2024 American Society Of Clinical Oncology Annual Meeting

Mizuho analyst Vijay Rakesh maintains Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) with a Buy and raises the price target from $935 to $960.

LRCX

Mizuho Maintains Buy on Lam Research, Raises Price Target to $960

Under the collaboration, Parexel will leverage Palantir&#39;s Foundry and Artificial Intelligence Platform (AIP) to further power its clinical data platform, focused on driving clinical trial efficiency while maintaining the highest level of safety and regulatory rigor. Parexel is the first CRO working with Palantir in this capacity, building on the companies&#39; existing collaboration over the past year.

PLTR

Parexel, Parexel Announce Multi-year Strategic Partnership To Leverage AI To Help Enhance And Accelerate Delivery Of Safe And Effective Clinical Trials

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) with a Buy and maintains $74 price target.

XOMA

HC Wainwright & Co. Reiterates Buy on XOMA, Maintains $74 Price Target

Mizuho analyst Ann Hynes maintains Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) with a Buy and raises the price target from $93 to $95.

Mizuho Maintains Buy on Encompass Health, Raises Price Target to $95

AssetMark stockholders will receive&nbsp;$35.25&nbsp;per share in cash, which represents a total equity valuation of approximately&nbsp;$2.7 billion. Under the terms of the agreement, GTCR will acquire a&nbsp;100%&nbsp;interest in the Company.&nbsp;AssetMark&#39;s Board of Directors has unanimously approved the transaction and recommended the transaction to its stockholders.&nbsp;
Upon completion of the transaction, AssetMark&#39;s common stock will no longer be listed on any public market.

AssetMark Financial Agrees To Be Acquired By Private Equity Firm GTCR For $35.25 Per Share In Cash

WIIM

American Airlines shares are trading higher after the company reported Q1 financial results.

LSI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYTS#NASDAQ">LYTS</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.15 by 40 percent. This is a 10.53 percent increase over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $108.186 million which beat the analyst consensus estimate of $105.571 million by 2.48 percent. This is a 7.90 percent decrease over sales of $117.470 million the same period last year.

Earnings Beats

LYTS

LSI Industries Q3 2024 Adj EPS $0.21 Beats $0.15 Estimate, Sales $108.186M Beat $105.571M Estimate

The former personal lawyer to Donald Trump, Michael Cohen, has pledged to stop all public commentary about the former president until after his testimony in the ongoing hush-money trial.
What Happened: On Thursday, Cohen announced on his X (formerly Twitter) account, &#8220;Despite not being the gagged defendant, out of respect for Judge Merchan and the prosecutors, I will cease posting anything about Donald on my X (formerly Twitter) account or on the Mea Culpa Podcast until after my trial testimony. See you all in a month (or more).&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Despite not being the gagged defendant, out of respect for Judge Merchan and the prosecutors, I will cease posting anything about Donald on my X (formerly Twitter) account or on the Mea Culpa Podcast until after my trial testimony. See you all in a month (or more). <a href="https://twitter.com/hashtag/TeamCohen?src=hash&amp;ref_src=twsrc%5Etfw">#TeamCohen</a> <a href="https://t.co/fzuQAffQRm">pic.twitter.com/fzuQAffQRm</a>
&mdash; Michael Cohen (@MichaelCohen212) <a href="https://twitter.com/MichaelCohen212/status/1783220136612131000?ref_src=twsrc%5Etfw">April 24, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Business Insider <a href="https://www.businessinsider.com/michael-cohen-trump-manhattan-merchan-hush-money-2024-4?IR=T">reported</a> that legal experts voiced concerns about Cohen&#8217;s ongoing public commentary on the case, which could potentially offer more material for Trump&#8217;s lawyers during cross-examination. Cohen&#8217;s choice to stay silent could be a strategic move to prevent jeopardizing his testimony.
Trump, who has consistently attacked Cohen&#8217;s credibility, is also being scrutinized for possibly violating Judge Juan Merchan&#8217;s gag order. Cohen&#8217;s forthcoming testimony is expected to be a significant event in the trial.
Why It Matters: Cohen is a <a href="https://www.benzinga.com/news/24/04/38240217/michael-cohen-suggests-public-will-be-surprised-by-bombshell-evidence-in-donald-trumps-hush-money-tr">key figure in the New York prosecutors</a>&#8216; accusations of falsified business records to hide hush money paid to adult film actress Stormy Daniels before the 2016 presidential election. He is also a crucial witness in Trump&#8217;s fraud trial.
See Also: <a href="https://www.benzinga.com/general/politics/24/04/38362005/donald-trump-may-soon-receive-36-million-more-djt-shares-key-milestone-ahead?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Donald Trump May Soon Receive An Additional $1.26B In DJT Shares: Key Milestone Ahead (UPDATED)</a>
It is worth noting that <a href="https://www.benzinga.com/news/24/04/38240217/michael-cohen-suggests-public-will-be-surprised-by-bombshell-evidence-in-donald-trumps-hush-money-tr">this case is moving forward</a> in contrast to Trump&#8217;s other criminal cases, which seem to be at a standstill. 
This also comes on the heels of Trump&#8217;s close allies including Boris Epshteyn, Mark Meadows, and Rudy Giuliani <a href="https://www.benzinga.com/news/24/04/38420233/trump-allies-giuliani-meadows-indicted-by-arizona-grand-jury-for-alleged-2020-election-subversion-ex">being indicted by an Arizona grand jury</a> for alleged involvement in attempts to overturn the 2020 election results.
Read Next: <a href="https://www.benzinga.com/news/24/04/38405064/anthony-scaramucci-says-nikki-haley-is-still-polling-nicely-in-pa-despite-ending-bid-against-trump-a?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Anthony Scaramucci Says Nikki Haley Is Still Polling &#8216;Nicely&#8217; In PA, Despite Ending Bid Against Trump: &#8216;And If You Are With Him: CRY&#8217;</a>
Photo by a katz on Shutterstock
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Politics

Former Trump Attorney Vows To Cease Public Criticism Of Ex-President Until Hush-Money Trial Is Over

Guidance

SPGI

S&P Global Sees FY24 Adj EPS Of $13.85 - $14.10 Vs. $14.11 Est.

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Buy and maintains $90 price target.

VKTX

HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target

Second quarter&nbsp;revenue is expected to reflect approximately&nbsp;20%&nbsp;year-on-year growth and sequential growth of&nbsp;8%, with Adjusted EBITDA Margin in an expected range of&nbsp;20%&nbsp;to&nbsp;21%, or up 200 to 300 basis points year-on-year and sequentially in both cases based on the mid-point of&nbsp;second quarter&nbsp;guidance.&quot;

XPRO

Expro Group Expects Q2 Revenue To Reflect Approximately 20% Y/Y Growth And Sequential Growth Of 8%

S&P Global Raises FY24 Revenue Outlook From 5.5% - 7.5% to 6.0% - 8.0%

By <a href="https://roboforex.com/?utm_source=benzinga.com&amp;utm_medium=pr&amp;utm_campaign=rf_en_external_article_25042024&amp;utm_content=analysis&amp;utm_term=forecast" style="color:#0563c1; text-decoration:underline">RoboForex</a> Analytical Department
The USD/JPY pair reached an all-time high on Thursday, touching the 155.50 level. This development comes as the Bank of Japan (BoJ) starts its two-day monetary policy meeting with widespread expectations that the interest rate will remain unchanged at zero. Investors are keenly watching for any aggressive signals from the BoJ, as further declines in the yen could prompt Tokyo to intervene in the currency market. However, any such intervention is expected to provide only a short-term respite for the yen.
The primary driver behind the yen&#39;s weakness remains the significant disparity in monetary policies between the Bank of Japan and the US Federal Reserve, particularly regarding interest rates. The current situation will likely persist if there is no shift in these policies.
Last week, BoJ Governor Kazuo Ueda indicated at the G-20 summit that the regulator might consider raising rates if the yen&#39;s weakness leads to a sustained increase in import prices. The BoJ is closely monitoring inflation trends, and should the consumer price index approach the 2% target, the bank may adopt a more decisive stance.
The yen has been on a consistent downward trajectory since 13 March this year, showing few signs of interruption.
USD/JPY technical analysis
<a href="https://www.benzinga.com/files/u117641/usdjpyh4_12.png"><img alt="" src="https://www.benzinga.com/files/u117641/usdjpyh4_12.png" style="height:716px; width:1596px" /></a>
On the H4 chart, USD/JPY found support at 153.65, and the fifth wave of growth is unfolding. The pair is expected to reach 155.85 soon. Following this, a corrective move to at least 154.60 (testing from above) is anticipated, potentially followed by further growth towards 156.56. This target represents the primary objective of the growth wave. This bullish scenario is technically supported by the MACD oscillator, whose signal line is above zero and trending upwards.
<a href="https://www.benzinga.com/files/u117641/usdjpyh1_10.png"><img alt="" src="https://www.benzinga.com/files/u117641/usdjpyh1_10.png" style="height:716px; width:1596px" /></a>
On the H1 chart, USD/JPY has established support at 154.55, with the upward structure aiming for 155.85. Currently, the growth to 155.73 has been executed. A slight retracement to 155.20 (testing from above) may occur next. After reaching this level, the likelihood of an ascent to 155.85 will be reassessed. This technical outlook is confirmed by the Stochastic oscillator, whose signal line is currently above 80, poised for a drop to around 50.
Disclaimer
Any forecasts contained herein are based on the author&#39;s particular opinion. This analysis may not be treated as trading advice. RoboForex bears no responsibility for trading results based on trading recommendations and reviews contained herein.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Japanese yen hits all-time low as BoJ meeting commences

Yappn

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for Yappn Stock (OTC:YPPN)

Friday, July 26, 2019